Clinical Trials Sponsored by InGeneron, Inc.

Total 35920 results

InGeneron, Inc.

Active, not recruiting

Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

Rotator Cuff Tear | Rotator Cuff Tendinitis

United States
InGeneron, Inc.

Completed

Safety and Efficacy of Adult Adipose-Derived Stem Cell Injection Into Partial Thickness Rotator Cuff Tears

Rotator Cuff Tears

United States
InGeneron, Inc.

Completed

Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears

Rotator Cuff Tear - Partial Thickness

United States
InGeneron, Inc.

Enrolling by invitation

A Longitudinal, Multi-Center Safety Study of Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears

Partial Thickness Rotator Cuff Tear

United States
InGeneron, Inc.

Unknown

Healing Chronic Venous Stasis Wounds With Autologous Cell Therapy

Wound, Nonpenetrating

United States
InGeneron, Inc.
Sanford Health

Recruiting

Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint

Osteoarthritis of Facet Joint of Lumbar Spine

United States
InGeneron, Inc.
Sanford Health

Recruiting

Healing Osteoarthritic Joints in the Wrist With Adult ADRCs

Osteoarthritis of the Wrist

United States
Fondren Orthopedic Group L.L.P.
InGeneron, Inc.

Completed

Thigh Pain After Total Knee Arthroplasty (TKA)

Osteoarthritis, Knee

United States
Fondren Orthopedic Group L.L.P.
InGeneron, Inc.

Completed

Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery

Articular Cartilage Defect Grade III or IV of the Knee

United States
SillaJen, Inc.
Regeneron Pharmaceuticals

Active, not recruiting

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Korea, Republic of
Vyriad, Inc.
Regeneron Pharmaceuticals

Recruiting

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Melanoma | Head and Neck Squamous Cell Carcinoma | Colo-rectal Cancer

United States, Brazil
Replimune Inc.
Regeneron Pharmaceuticals

Active, not recruiting

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma

Spain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
Sensei Biotherapeutics, Inc.
Regeneron Pharmaceuticals

Recruiting

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Cervix Cancer | Advanced Solid Tumor | Advanced Cancer | Colon Cancer | Thyroid Cancer | Solid Tumor... and other conditions

United States
Sanofi
Regeneron Pharmaceuticals; NSABP Foundation Inc

Completed

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen (VELOUR)

Neoplasm Metastasis | Colorectal Neoplasms

Italy, Austria, Estonia, Spain, South Africa, Belgium, Puerto Rico, United Kingdom, Sweden, United States, Argentina, Australia, Brazil, Chile, Czech Republic, Denmark, France, Germany, Greece, Korea, Republic of, Netherlands, New... and more
Regeneron Pharmaceuticals
Sanofi; Aimmune Therapeutics, Inc.

Completed

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Peanut Allergy

United States
Intermountain Health Care, Inc.
Regeneron Pharmaceuticals

Not yet recruiting

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome (MAbPACs)

Post-acute COVID-19 (PACS), or "Long COVID" Syndrome

United States
Immune-Onc Therapeutics
Regeneron Pharmaceuticals

Active, not recruiting

First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, Spain, Malaysia, France, Taiwan, Italy, Poland, United States, Thailand, United Kingdom, Turkey, Belgium, Czechia
Regeneron Pharmaceuticals

Recruiting

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Recruiting

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations (ENSEMBLE)

Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF) | Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes

United States
Regeneron Pharmaceuticals

Not yet recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

Non-alcoholic Steatohepatitis (NASH) | Metabolic Dysfunction Associated Steatohepatitis (MASH)

United States, Korea, Republic of, Puerto Rico, Japan
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Recruiting

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG) (CEMI-LUNG)

Non-small Cell Lung Cancer

Germany, Austria, France
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1)

Advanced Solid Tumors

United States
Regeneron Pharmaceuticals

Recruiting

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Celiac Disease

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Regeneron Pharmaceuticals

Recruiting

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Advanced Malignancies

Japan
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Venous Thromboembolism

Poland, Latvia, Canada, Belgium, Bulgaria, Hungary, Lithuania
Regeneron Pharmaceuticals

Suspended

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Australia
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
Regeneron Pharmaceuticals

Completed

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Paroxysmal Nocturnal Hemoglobinuria

Korea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
Regeneron Pharmaceuticals

Available

Compassionate Use of Dupilumab

Bullous Pemphigoid | Pediatric Asthma | Pediatric Eosinophilic Esophagitis (EoE) | Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Regeneron Pharmaceuticals

Completed

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP)

United States
Regeneron Pharmaceuticals

Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ORCHID)

Diffuse Large B-Cell Lymphoma

Austria, France, Germany, United Kingdom
Regeneron Pharmaceuticals

Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma (FLORA)

Relapsed/Refractory Follicular Lymphoma

Austria, France, Germany, United Kingdom
Regeneron Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Retinopathy of Prematurity

United States, Bulgaria, Colombia, Korea, Republic of, Romania, Russian Federation, Taiwan, Thailand, Turkey, Vietnam
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria
Regeneron Pharmaceuticals

Available

Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

CD55-Deficient Protein-Losing Enteropathy
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
Regeneron Pharmaceuticals

Available

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Ebola Virus Disease
Regeneron Pharmaceuticals

Available

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Multiple Myeloma
Regeneron Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Hong Kong, Hungary, Korea, Republic of, Malaysia, United Kingdom
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Regeneron Pharmaceuticals

Terminated

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
Regeneron Pharmaceuticals

Completed

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Homozygous Familial Hypercholesterolemia

United States, Australia, Austria, Netherlands, Taiwan, Ukraine

Clinical Trials Sponsored by InGeneron, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations